FMK-MEA | 赛默飞Alfa aesar官网

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FMK-MEA

FMK-MEA是一种有效和选择性的p90核糖体S6激酶 (p90 Ribosomal S6 Kinase (RSK)) 抑制剂。

FMK-MEA Chemical Structure

CAS No. : 1414811-15-6

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.
IC₅₀ & Target	p90 RSK^[1]
体外研究 (In Vitro)	FMK-MEA is a water-soluble derivative of fmk. FMK-MEA treatment inhibits RSK2 kinase activity in diverse, highly invasive human cancer cell lines including 212LN, M4e, A549, and SKBR3 cells. Treatment with the RSK-specific inhibitor FMK-MEA significantly attenuates RSK2 activity, as assessed by the phosphorylation levels of Ser-386 and the consequent invasive ability of A549 cells^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)	FMK-MEA treatment (80 mg/kg/day for 16 days by intraperitoneal injection) in highly metastatic M4e cell xenograft nude mice results in a significant attenuation of LN metastasis. FMK-MEA treatment has no effect on the tumor size, and the proliferation rate of the primary tumor^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量	399.46
Formula	C₂₁H₂₆FN₅O₂
CAS 号	1414811-15-6
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Li D, et al. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J Biol Chem. 2013 Nov 8;288(45):32528-38.

Animal Administration ^[1]	Mice^[1] For FMK-MEA treatment, each of the nude mice (^{athymic nu/nu, female, 4-6 weeks old}) are injected with 0.5×10⁶cells/100 μL of PBS submandibular to the mylohyoid muscle. On day 5 after injection, mice are divided into two groups with similar average weights with each group receiving either FMK-MEA or PBS. Each mouse is administered ^{80 mg/kg of FMK-MEA} daily by intraperitoneal injection from 5 days after the xenograft for 16 days total. The control group receives PBS alone on the same schedule. Tumor growth is recorded. Mice are sacrificed after 16 days post drug treatment^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Li D, et al. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J Biol Chem. 2013 Nov 8;288(45):32528-38.

Animal Administration
^[1]

Mice^[1]

For FMK-MEA treatment, each of the nude mice (^{athymic nu/nu, female, 4-6 weeks old}) are injected with 0.5×10⁶cells/100 μL of PBS submandibular to the mylohyoid muscle. On day 5 after injection, mice are divided into two groups with similar average weights with each group receiving either FMK-MEA or PBS. Each mouse is administered ^{80 mg/kg of FMK-MEA} daily by intraperitoneal injection from 5 days after the xenograft for 16 days total. The control group receives PBS alone on the same schedule. Tumor growth is recorded. Mice are sacrificed after 16 days post drug treatment^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Li D, et al. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J Biol Chem. 2013 Nov 8;288(45):32528-38.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务